Gilead Sciences, Inc.’s stock price soars to $122.81, marking a bullish 4.21% increase

Gilead Sciences, Inc. (GILD)

122.81 USD +4.96 (+4.21%) Volume: 15.84M

Gilead Sciences, Inc.’s stock price soared to 122.81 USD, marking a notable trading session increase of +4.21%, with a hefty trading volume of 15.84M. This impressive performance underscores a robust Year-To-Date (YTD) percentage change of +32.95%, highlighting GILD as a formidable player in the stock market game.

Latest developments on Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) has seen a surge in its stock price today, reaching a 52-week high of $121.84. The company’s strong performance is attributed to its HIV treatments, which have propelled its stocks above competitors in the market. Additionally, Gilead recently presented new research data at EACS 2025, showcasing its commitment to driving scientific innovation in HIV treatment and prevention. The company’s success has caught the attention of investors, with Goldman Sachs raising Gilead Sciences’ price target to $108. Furthermore, Gilead Foundation’s partnership with Boys & Girls Clubs of America to promote STEM careers highlights the company’s dedication to making a positive impact beyond the stock market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma